Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Orteronel |
| Synonyms | |
| Therapy Description |
Orteronel (TAK-700) inhibits CYP17A1, resulting in reduced androgen production and potentially leading to decreased growth of androgen-dependent tumors (PMID: 24799061, PMID: 32223238). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Orteronel | TAK-700|TAK700|TAK 700 | Hormone - Anti-androgens 57 | Orteronel (TAK-700) inhibits CYP17A1, resulting in reduced androgen production and potentially leading to decreased growth of androgen-dependent tumors (PMID: 24799061, PMID: 32223238). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01809691 | Phase III | Orteronel Bicalutamide | S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
| NCT01990209 | Phase II | Orteronel | Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) | Completed | USA | 0 |